IRadimed Corp. Hits New 52-Week High of $85.00, Up 97.91%
IRadimed Corp. has achieved a new 52-week high of USD 85.00, reflecting a strong one-year return of 97.91%. The company, with a market capitalization of USD 914 million, shows effective management through a 21.91% return on equity and robust operational performance, including significant cash flow and net sales.
IRadimed Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 85.00 on November 3, 2025. This achievement underscores the company's robust performance, with a remarkable one-year return of 97.91%, significantly outpacing the S&P 500's 19.89% return during the same period.The company's market capitalization stands at USD 914 million, reflecting its position within the small-cap segment. IRadimed Corp. boasts a price-to-earnings (P/E) ratio of 39.00, indicating a premium valuation compared to its peers. Additionally, the company maintains a healthy return on equity (ROE) of 21.91%, showcasing effective management efficiency.
Financially, IRadimed has demonstrated strong operational performance, with operating cash flow reaching a peak of USD 19.4 million and net sales hitting USD 20.41 million in the latest quarter. The company also benefits from a low debt-to-equity ratio of -0.56, further solidifying its financial stability. With a 52-week low of USD 47.48, the stock's upward trajectory highlights its growth potential within the competitive landscape of the pharmaceuticals and biotechnology industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
